Cyclic Peptide
Discovery of Cyclic Peptides Targeting β-Catenin
Design orally bioavailable cyclic peptides targeting β-catenin/BCL9 protein-protein interactions (PPI)
Background
• The Wnt/β-catenin signaling pathway is one of the most frequently activated pathways in cancer.
• Disrupting the β-catenin/BCL9 interaction effectively blocks Wnt/β-catenin signaling, offering a promising therapeutic strategy.
• Goal: Design orally bioavailable cyclic peptides that target β-catenin/BCL9 protein-protein interactions (PPI).
Approach
Results
Our mission is to democratize computational drug discovery tools and empower researchers and organizations worldwide.